Curapel has 3 core patent families protecting natural compounds for use in the treatment of 1) eczema, 2) psoriasis and 3) skin pigmentation disorders. Curapel already has its own product (pellamex) on the market as a nutritional supplement for eczema and has recently signed a licence deal for this product to a tier 1 pharma and consumer healthcare products manufacturer. The psoriasis product is a topical cream designated as a Class 1 Medical Device (CE marked) and is now ready for licensing. The third product for skin pigmentation requires further product development and is anticipated for market launch in late 2020 / early 2021.